EPIGENETIC PHARMACEUTICAL DEVELOPMENT TARGETING CANCER AND PARASITIC DISEASES
With EU funding, Kancera has for three years been developing drugs to treat the serious parasitic disease schistosomiasis, which kills around 280,000 people every year. These drug-like substances are owned by Kancera jointly with its EU partners for the treatment of parasitic diseases.
The EU-financed project (A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics) is coordinated by the Institut Pasteur and includes collaborations with epigenetic experts from Germany, France, UK, Italy, Australia and Brazil. Kancera´s primary focus during the first phase of the project is to optimize the pharmaceutical properties of the anti-parasitic substances.
The project focus on target proteins in the following diseases (parasites): Malaria (Plasmodium falciparum), Schistosomiasis (Schistosoma mansoni), Leishmaniasis (Leishmania) and Chagas disease (Trypanosoma cruz). Kancera is the only pharmaceutical development company in the A PARADDISE consortium and is well positioned to commercialize the drug candidates that the company develops and owns together with its partners.
Kancera has continued the optimization of anti-parasitic compounds which Kancera successfully initiated during the completed EU funded project SETTREND. The project work mainly focused on the further development of anti-parasitic compounds that the company previously developed.
More than 150 new substances against parasitic target proteins have been synthesized since the start of the project. The academic groups in the consortium are continuously testing the effect of synthesized compounds against various types of parasites.